Clinical trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Dosing of Exidavnemab in Patients With Mild to Moderate Parkinson's Disease on Stable Symptomatic Parkinson's Disease Medication and in Patients With Multiple System Atrophy
NCT06671938 is registered in ClinicalTrials.gov with BioArctic AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Dosing of Exidavnemab in Patients With Mild to Moderate Parkinson's Disease on Stable Symptomatic Parkinson's Disease Medication and in Patients With Multiple System Atrophy
- Lead sponsor
- BioArctic AB
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 24, 2024
- Completion date
- August 10, 2026
- Enrollment
- 38 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.